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Abstract
Acromegaly can be treated with several medical modalities. The growth hormone (GH) receptor antagonist pegvisomant,
in particular, is able to reduce serum insulin-like growth factor I (IGF-I) concentrations to almost any desired level. Along
with this important achievement come other practical issues. The most important is that IGF-I also has metabolic actions,
especially the control of serum glucose concentrations. As somatostatin analogues and pegvisomant have their own intrin-
sic differential effects on serum GH levels and actions as well as on serum IGF-I levels and actions, it should not automati-
cally be assumed that absolute concentrations of these parameters of disease activity reflect the same levels of action. In the
ideal situation we should be able to develop treatment of specific target levels for both GH and IGF-I that might even be
patient-specific as well. To date we have not moved as far as this, but awareness of treatment-specific differential effects
might help us to understand some of the signs and symptoms that we encounter in acromegalic patients.
(Pol J Endocrinol 2007; 58 (4): 361–363)
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Streszczenie
W akromegalii możliwe są różne sposoby farmakoterapii. Antagonista receptora hormonu wzrostu (GH, growth hormone)
— pegvisomant powoduje obniżenie stężenia insulinopodobnego czynnika wzrostu-I (IGF-I, insulin-like growth factor I) do
oczekiwanych wartości. Następstwem tego efektu jest wiele praktycznych konsekwencji. Najważniejsze jest to, że działa-
nie metaboliczne IGF-I odgrywa szczególną rolę w regulacji stężenia glukozy. Podobnie do analogów somatostatyny pe-
gvisomant wykazuje własny wewnętrzny zróżnicowany wpływ na stężenia w surowicy oraz działania GH i IGF-I. Na tej
podstawie nie można automatycznie zakładać, że stężenia tych wskaźników aktywności choroby odzwierciedlają taki sam
poziom ich działania. W idealnej sytuacji powinna istnieć możliwość rozwoju specyficznej terapii celowanej, ukierunko-
wanej na poziomy zarówno GH i IGF-I, które mogłoby równocześnie być specyficzne dla pacjenta. Obecnie, nie dysponu-
jemy jeszcze takimi osiągnięciami, ale realizacja typowych dla terapii zróżnicowanych efektów mogłaby pomóc nam zro-
zumieć niektóre objawy, które stwierdza się u chorych na akromegalię.
(Endokrynol Pol 2007; 58 (4): 361–363)
Słowa kluczowe: akromegalia, analogi somatostatyny, antagonista receptora hormonu wzrostu, metabolizm glukozy i insuliny
As all the available medications for the treatment of pi-
tuitary tumours were introduced more than 10 years
ago except for the medical possibilities for treating so-
matotropinomas, this section only addresses the achie-
vements that have been made in controlling the signs
and symptoms of acromegaly.
Somatostatin analogues
The medical treatment modalities available for acrome-
galy are the dopamine-agonists (bromocriptine, quina-
golide and cabergoline) and somatostatin analogues
(octreotide and lanreotide). Dopamine agonists have
limited efficacy and tolerability and are, in general, less
effective than the somatostatin analogues [1, 2]. Long-
acting somatostatin analogues are given every two to
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four weeks and normalise serum IGF-I levels in about
65% of patients [3, 4]. This still leaves at least one third
of patients eligible for a more effective medical thera-
py. Somatostatin analogues have been and are used for
acromegalic individuals to suppress GH secretion; ho-
wever, they also inhibit TSH, insulin, glucagon and neu-
ropeptide secretion.
Pegvisomant
GH is normally cleared via the kidneys and/or GH re-
ceptor (GHR) internalisation and has a half-life of ap-
proximately 15–20 minutes. Pegvisomant is a GH ana-
logue that includes a single amino acid substitution (ly-
sine for glycine) at position 120, which, alone, genera-
tes the GH antagonist. Additional changes include
amino acid substitutions within binding site 1 (which
are thought to increase the affinity of the molecule to
the GHR) and a further modification by the addition of
polyethylene glycol moieties that increase the half-life
and reduce the immunogenicity of the molecule. Inte-
restingly, recent data has shown that the eight amino
acid substitutions in Site 1 do not actually increase the
binding affinity of the molecule to the GHR. However,
the eight amino acid substitutions remove two poten-
tial sites for PEG addition, namely at Lys168 and Lys172,
which are within the native binding Site 1 [5]. Further-
more, these eight additional mutations in Site 1 do not
interfere with the preformed receptor dimer or recep-
tor internalisation [5].
Following GH binding to the GHR, the complex is
internalised [6–9]. However, pegvisomant cannot trans-
duce intracellular GH-specific signals. Pegvisomant
does not inhibit dimer formation but prevents “proper”
or functional dimerisation of the GHR [10].
The clinical use of pegvisomant
in acromegaly
Several important studies have established the efficacy
of long-term pegvisomant therapy in the treatment of
acromegaly [11–13]. In a double-blind placebo-control-
led study 112 patients with active acromegaly were tre-
ated with either placebo or one of three subcutaneous
dosages (10, 15 or 20 mg) of pegvisomant for 12 weeks
[12]. Parameters for the efficacy of pegvisomant were
serum IGF-I and GH concentrations, as well as a qu-
estionnaire evaluating soft-tissue swelling, arthralgia,
headache, excessive perspiration and fatigue. In the
pegvisomant-treated patients a dose-related improve-
ment in symptoms and signs was observed. Serum IGF-
I concentrations decreased significantly in all treatment
groups, and 82% of patients treated with the highest
dose achieved normal serum IGF-I concentrations at the
end of the study. Although pegvisomant seemed a very
effective drug for the treatment of acromegaly [12], qu-
estions concerning its safety and efficacy in the long
term remained [14]. In one patient with a clinically im-
portant increase in tumour-size under pegvisomant
monotherapy, co-treatment with octreotide halted fur-
ther tumour growth and resulted in a synergistic de-
crease in serum IGF-I concentrations [15]. Daily subcu-
taneous administration of pegvisomant is thus the most
effective medical treatment for acromegaly to date. The
rationale for using a combination of somatostatin ana-
logues and pegvisomant is based on the assumption that
less pegvisomant is needed when there is less endoge-
nous GH with which to compete. Indeed, because of
the presence of high concentrations of somatostatin
analogue in serum and unlike what can be observed
during pegvisomant monotherapy, the combined tre-
atment of a somatostatin analogue with pegvisomant
is not accompanied by an increase in serum GH con-
centrations.
Another rationale for the combination therapy is that
somatostatin decreases insulin secretion [16–20]. Portal
insulin up-regulates hepatic GHR biosynthesis in a con-
centration-dependent manner. As GHR translocation
to the cellular surface is suppressed by insulin, GHR
surface availability will be the net result of these diver-
gent effects [21]. Therefore lower portal vein insulin le-
vels due to somatostatin analogue therapy will decre-
ase the number of available GHR at the cell surface of
the liver. This implies that the efficacy of the GHR anta-
gonist pegvisomant is likely to be increased by the pre-
sence of a somatostatin analogue for two reasons: the
first is that the level of endogenous GH is reduced sin-
ce somatostatin analogues inhibit GH secretion by the
pituitary adenoma, while the second is that somatosta-
tin analogues reduce the number of GHR in the liver
by reducing insulin secretion so that the liver becomes
relatively GH-resistant. Together, these mechanisms
reduce the amount of pegvisomant that is necessary to
block GH action in order to normalise the serum total
IGF-I concentration. Indeed, Feenstra et al. observed
that combined treatment with monthly long-acting so-
matostatin analogue injections and weekly subcutane-
ous pegvisomant injections is a rational medical treat-
ment combination [22]. This therapy seems to be safe
and effective in normalising serum IGF-1 concentration
in more than 90% of patients with active acromegaly
who cannot be controlled with long-acting somatosta-
tin therapy alone. This efficacy rate is equal to the effi-
cacy of pegvisomant monotherapy. In their study no
increase whatsoever in pituitary tumour volume could
be observed in any of the patients, which might indica-
te that with respect to pituitary tumour size combined
therapy is safer than pegvisomant monotherapy. The
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combined therapy might induce mild disturbances in
liver function tests, however.
In conclusion, pegvisomant is the first member of
a new class of drugs against acromegaly. It seems to have
exhibited hardly any side-effects to date, although data
on long-term safety still need to be gathered. Potential
improvement in efficacy and perhaps even safety with
regard to tumour size may be gained from the combina-
tion of somatostatin analogues and pegvisomant.
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